| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2019 |
| Sales | 1,300 | 200 | 1,630 | 1,320 | 13,210 |
| Sales Growth | +550.00% | -87.73% | +23.48% | -90.01% | unch |
| Net Income | -140,060 | 1,687,570 | -154,960 | -115,330 | -51,400 |
| Net Income Growth | -108.30% | +1,189.04% | -34.36% | -124.38% | unch |
Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Inhibrx Inc. is a clinical-stage biopharmaceutical company. It focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
Fiscal Year End Date: 12/31